Assessment of the Safety of Olmesartan in Combination with Sorafenib in Mice Bearing Ehrlich’s Ascites Carcinoma

Mohammad M. Abd-Alhaseeb, Sawsan A. Zaitone, Soad H. Abou-El-Ela, Yasser M. Moustafa

Department of Bio- chemistry, Faculty of Pharmacy & Pharmaceutical Industries, Sinai University, Arish, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy & Pharmaceutical Industries, Sinai University, Arish, Egypt.
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Suez Canal University, Ismailia, Egypt.

DOI: 10.4236/jct.2013.48160                

Abstract

Sorafenib was the first multikinase inhibitor to be approved for use in metastatic renal cell carcinoma. Olmesartan medoxomil used in treatment of hypertension and was reported to inhibit angiogenesis in several models. The present study was designed to assess the safety of a combination of sorafenib plus olmesartan compared to monotherapies in mice bearing Ehrlich’s ascites carcinoma cell line. Mice were divided to seven groups, 1) normal mice, 2) Ehrlich’s ascites carcinoma control, 3 - 5) olmesartan (3, 10, 30 mg/kg/day), respectively, 6) sorafenib (30 mg/kg/day) and 7) the combination group: mice received olmesartan (30 mg/kg/day) plus sorafenib. All drug treatments continued for 21 days. At the end of the experiment, a complete blood count was performed and kidney and liver functions were estimated. The combination therapy produced a non-significant change in most of the measurements of complete blood count and liver enzymes when compared to normal animals. On the other hand, the combined therapy significantly increased blood urea nitrogen when compared to normal group but did not change the serum creatinine level. Concomitant administration of olmesartan with sorafenib did not significantly augment the toxicity of the later. Therefore; olmesartan might be a safe candidate with sorafenib in treatment of cancer if clinical data proved the benefit of this combination.

Keywords

Mice; Ehrlich’s Ascites Carcinoma; Olmesartan; Sorafenib

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	J. Bellmunt, T. Eisen, M. Fishman and D. Quinn, “Experience with Sorafenib and Adverse Event Management,” Critical Reviews in Oncology/Hematology, Vol. 78, No. 1, 2011, pp. 24-32. http://dx.doi.org/10.1016/j.critrevonc.2010.03.006
[2]	N. Bhojani, C. Jeldres, J. J. Patard, P. Perrotte, N. Suardi, G. Hutterer, F. Patenaude, S. Oudard and P. I. Karakiewicz, “Toxicities Associated with the Administration of Sorafenib, Sunitinib, and Temsirolimus and Their Management in Patients with Metastatic Renal Cell Carcinoma,” European Urology, Vol. 53, No. 5, 2008, pp. 917-930. http://dx.doi.org/10.1016/j.eururo.2007.11.037
[3]	S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet and M. Lynch, “Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling,” Molecular Cancer Therapeutics, Vol. 7, No. 10, 2008, pp. 3129-3140. http://dx.doi.org/10.1158/1535-7163.MCT-08-0013
[4]	J. C. Lin, C. L. Liu, J. J. Lee, T. P. Liu, W. C. Ko, Y. C. Huang, C. H. Wu and Y. J. Chen, “Sorafenib Induces Autophagy and Suppresses Activation of Human Macrophage,” International Immunopharmacology, Vol. 15, No. 2, 2013, pp. 333-339. http://dx.doi.org/10.1016/j.intimp. 2013.01.006
[5]	F. A. Schutz, Y. Je and T. K. Choueiri, “Hematologic Toxicities in Cancer Patients Treated with the Multi-Tyrosine Kinase Sorafenib: A Meta-Analysis of Clinical Trials,” Critical Reviews in Oncology/Hematology, Vol. 80, No. 2, 2011, pp. 291-300. http://dx.doi.org/10.1016/j.critrevonc. 2010.11.007
[6]	J. M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, J. F. Blanc, A. C. de Oliveira, A. Santoro, J. L. Raoul, A. Forner, M. Schwartz, C. Porta, S. Zeuzem, L. Bolondi, T. F. Greten, P. R. Galle, J. F. Seitz, I. Borbath, D. Haussinger, T. Giannaris, M. Shan, M. Moscovici, D. Voliotis, J. Bruix and S. I. S. Group, “Sorafenib in Advanced Hepatocellular Carcinoma,” The New England Journal of Medicine, Vol. 359, 2008, pp. 378-390. http://dx.doi.org/10.1056/NEJMoa0708857
[7]	L. S. Wood, “Managing the Side Effects of Sorafenib and Sunitinib,” Community Oncology, Vol. 3, No. 9, 2006, pp. 558-562. http://dx.doi.org/10.1016/S1548-5315(11)70751-3
[8]	J. A. Brousil and J. M. Burke, “Olmesartan Medoxomil: An Angiotensin II-Receptor Blocker,” Clinical Therapeutics, Vol. 25, No. 4, 2003, pp. 1041-1055. http://dx.doi.org/10.1016/S0149-2918(03)80066-8
[9]	V. Sukumaran, P. T. Veeraveedu, N. Gurusamy, A. P. Lakshmanan, K. Yamaguchi, M. Ma, K. Suzuki, M. Nagata, R. Takagi, M. Kodama and K. Watanabe, “Olmesartan Attenuates the Development of Heart Failure after Experimental Autoimmune Myocarditis in Rats through the Modulation of ANG 1-7 Mas Receptor,” Molecular and Cellular Endocrinology, Vol. 351, No. 2, 2012, pp. 208-219. http://dx.doi.org/10.1016/j.mce.2011.12.010
[10]	H. Huynh, J. W. Lee, P. K. Chow, V. C. Ngo, G. B. Lew, I. W. Lam, H. S. Ong, A. Chung and K. C. Soo, “Sorafenib Induces Growth Suppression in Mouse Models of Gastrointestinal Stromal Tumor,” Molecular Cancer Therapeutics, Vol. 8, No. 1, 2009, pp. 152-159. http://dx.doi.org/10.1158/1535-7163.MCT-08-0553
[11]	M. Tsuda, M. Iwai, J. M. Li, H. S. Li, L. J. Min, A. Ide, M. Okumura, J. Suzuki, M. Mogi, H. Suzuki and M. Horiuchi, “Inhibitory Effects of AT1 Receptor Blocker, Olmesartan, and Estrogen on Atherosclerosis via Anti-Oxidative Stress,” Hypertension, Vol. 45, No. 4, 2005, pp. 545-551. http://dx.doi.org/10.1161/01.HYP.0000157409.88971.fc
[12]	F. J. Gella, T. Olivella, M. Cruz Pastor, J. Arenas, R. Moreno, R. Durban and J. A. Gomez, “A Simple Procedure for the Routine Determination of Aspartate Aminotransferase and Alanine Aminotransferase with Pyridoxal Phosphate,” Clinica Chimica Acta, Vol. 153, No. 3, 1985, pp. 241-247. http://dx.doi.org/10.1016/0009-8981(85)90358-4
[13]	M. Peake and M. Whiting, “Measurement of Serum Creatinine—Current Status and Future Goals,” The Clinical Biochemist Reviews, Vol. 27, 2006, pp. 173-184.
[14]	M. A. Hamed, N. S. El-Rigal and S. A. Ali, “Effects of Black Seed Oil on Resolution of Hepato-Renal Toxicity Induced Bybromobenzene in Rats,” European Review for Medical and Pharmacological Sciences, Vol. 17, 2013, pp. 569-581.
[15]	S. R. Gangar and A. Koul, “Effects of Azadirachta Indica on Certain Hematological Parameters during Benzo(a)pyrene Induced Murine Forestomach Tumorigenesis,” European Review for Medical and Pharmacological Sciences, Vol. 14, 2010, pp. 1055-1072.
[16]	J. P. Fillastre, G. Viotte, J. P. Morin and B. Moulin, “Nephrotoxicity of Antitumoral Agents,” Advances in Nephrology from the Necker Hospital, Vol. 17, 1988, pp. 175-218.
[17]	L. S. Wood, “Management of Vascular Endothelial Growth Factor and Multikinase Inhibitor Side Effects,” Clinical Journal of Oncology Nursing, Vol. 13, Suppl, 2009, pp. 13-18. http://dx.doi.org/10.1188/09.CJON.S2.13-18
[18]	Y. Je, F. A. Schutz and T. K. Choueiri, “Risk of Bleeding with Vascular Endothelial Growth Factor Receptor Tyrosine-Kinase Inhibitors Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials,” The Lancet Oncology, Vol. 10, No. 10, 2009, pp. 967-974. http://dx.doi.org/10.1016/S1470-2045(09)70222-0
[19]	Y. Wang, J. Gao, D. Zhang, J. Zhang, J. Ma and H. Jiang, “New Insights into the Antifibrotic Effects of Sorafenib on Hepatic Stellate Cells and Liver Fibrosis,” Journal of Hepatology, Vol. 53, No. 1, 2010, pp. 132-144. http://dx.doi.org/10.1016/j.jhep.2010.02.027
[20]	M. Gabbianelli, E. Pelosi, E. Montesoro, M. Valtieri, L. Luchetti, P. Samoggia, L. Vitelli, T. Barberi, U. Testa, S. Lyman, et al., “Multi-Level Effects of Flt3 Ligand on Human Hematopoiesis: Expansion of Putative Stem Cells and pRoliferation of Granulomonocytic Progenitors/ Monocytic Precursors,” Blood, Vol. 86, 1995, pp. 1661-1670.
[21]	B. Uz, S. C. Tatonyan, M. Sayitoglu, Y. Erbilgin, O. H. Ng, Y. Buyukasik, N. Sayinalp, S. Aksu, H. Goker, O. I. Ozcebe, U. Ozbek and I. C. Haznedaroglu, “Local Hematopoietic Renin-Angiotensin System in Myeloid versus Lymphoid Hematological Neoplastic Disorders,” Journal of Renin-Angiotensin-Aldosterone System, 2012, in press. http://dx.doi.org/10.1177/1470320312464677
[22]	N. Kurikawa, M. Suga, S. Kuroda, K. Yamada and H. Ishikawa, “An Angiotensin II Type 1 Receptor Antagonist, Olmesartan Medoxomil, Improves Experimental Liver Fibrosis by Suppression of Proliferation and Collagen Synthesis in Activated Hepatic Stellate Cells,” British Journal of Pharmacology, Vol. 139, No. 6, 2003, pp. 1085-1094. http://dx.doi.org/10.1038/sj.bjp.0705339
[23]	K. Funao, M. Matsuyama, Y. Kawahito, H. Sano, J. Chargui, J. L. Touraine, T. Nakatani and R. Yoshimura, “Telmisartan Is a Potent Target for Prevention and Treatment in Human Prostate Cancer,” Oncology Reports, Vol. 20, 2008, pp. 295-300.
[24]	M. M. Nagib, M. G. Tadros, M. I. Elsayed and A. E. Khalifa, “Anti-Inflammatory and Anti-Oxidant Activities of Olmesartan Medoxomil Ameliorate Experimental Colitis in Rats,” Toxicology and Applied Pharmacology, Vol. 271, No. 1, 2013, pp. 106-113. http://dx.doi.org/10.1016/j.taap.2013.04.026
[25]	K. Shimada, T. Murayama, M. Yokode, T. Kita, M. Fujita and C. Kishimoto, “Olmesartan, a Novel Angiotensin II Type 1 Receptor Antagonist, Reduces Severity of Atherosclerosis in Apolipoprotein E Deficient Mice Associated with Reducing Superoxide Production,” Nutrition, Metabolism & Cardiovascular Diseases, Vol. 21, No. 9, 2011, pp. 672-678. http://dx.doi.org/10.1016/j.numecd. 2009.12.016
[26]	P. Sengupta, U. Nandi and T. K. Pal, “Development of Safety Profile Evaluating Pharmacokinetics, Pharmacodynamics and Toxicity of a Combination of Pioglitazone and Olmesartan Medoxomil in Wistar Albino Rats,” Regulatory Toxicology and Pharmacology, Vol. 62, No. 1, 2012, pp. 7-15. http://dx.doi.org/10.1016/j.yrtph.2011.12.008